Take2 licenses Grail’s nasopharyngeal cancer detection platform

Grail Inc. (Menlo Park, Calif.) granted Take2 Health Ltd. (Hong Kong, China) exclusive, worldwide rights to a portfolio of technology for the early detection of nasopharyngeal cancer. Financial terms were not disclosed.

Grail spokesperson

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE